In the era of immunotherapy, human cancers can be divided into three types according to the status of the anti-tumor immune response, that is, immunophenotype: inflamed, excluded and desert. Inflammatory cancer generally refers to tumors with a high expression level of PD-L1 in cancer cells and more infiltrating immune cells and tumor-infiltrating lymphocytes (TILs); These tumors are sensitive to immune checkpoint inhibitors (CPI). Excluded tumors refers to a large number of T cells in the tumor stroma, but these T cells cannot penetrate the stromal infiltration tumor due to the highly inhibitory microenvironment. This kind of tumor often has a poor response to CPI. Desert type tumors lack the infiltration of T cells and immune cells even in the stroma. They are truly an "immune desert" without grass. Immunophenotypes are associated with a variety of different mechanisms, including Wnt/ ß- Catenin signal, till reduction, PI3K-Akt / FGFR3 signal mutation, tumor mutational burden (TMB), etc. The overall clinical challenge remains to determine the threshold of inflammatory tumors and to identify specific drivers associated with specific phenotypes. The clinical transformation of combination therapy needs to determine the appropriate patient population to transform desert or repulsive tumors into inflammatory tumors. The availability of tumor genomic databases such as The Cancer Genome Atlas (TCGA), International Cancer Genome Consortium (ICGC), Therapeutically Applicable Research to Generate Effective Treatments (TARGET) and Gene Expression Omnibus (GEO) has enabled researchers to mine multi-omic cancer data to come up with an improved understanding of complex interactions between immunophenotype, cold and hot tumor conversion and immune checkpoint therapy.
We invite contributions of original research and reviews by using tumor genomic databases and bioinformatics tools covering the following topics of interest:
1) Different immunophenotypes as biomarkers in the prognosis in tumors.
2) Tumor mutational burden (TMB) and tumor immunotherapy response.
3) Therapeutic targeting of tumor immunophenotypes in the prevention of tumors.
4) Relationship between pathways and immunotherapy.
5) immune checkpoint signaling and tumor immunotherapy.
In the era of immunotherapy, human cancers can be divided into three types according to the status of the anti-tumor immune response, that is, immunophenotype: inflamed, excluded and desert. Inflammatory cancer generally refers to tumors with a high expression level of PD-L1 in cancer cells and more infiltrating immune cells and tumor-infiltrating lymphocytes (TILs); These tumors are sensitive to immune checkpoint inhibitors (CPI). Excluded tumors refers to a large number of T cells in the tumor stroma, but these T cells cannot penetrate the stromal infiltration tumor due to the highly inhibitory microenvironment. This kind of tumor often has a poor response to CPI. Desert type tumors lack the infiltration of T cells and immune cells even in the stroma. They are truly an "immune desert" without grass. Immunophenotypes are associated with a variety of different mechanisms, including Wnt/ ß- Catenin signal, till reduction, PI3K-Akt / FGFR3 signal mutation, tumor mutational burden (TMB), etc. The overall clinical challenge remains to determine the threshold of inflammatory tumors and to identify specific drivers associated with specific phenotypes. The clinical transformation of combination therapy needs to determine the appropriate patient population to transform desert or repulsive tumors into inflammatory tumors. The availability of tumor genomic databases such as The Cancer Genome Atlas (TCGA), International Cancer Genome Consortium (ICGC), Therapeutically Applicable Research to Generate Effective Treatments (TARGET) and Gene Expression Omnibus (GEO) has enabled researchers to mine multi-omic cancer data to come up with an improved understanding of complex interactions between immunophenotype, cold and hot tumor conversion and immune checkpoint therapy.
We invite contributions of original research and reviews by using tumor genomic databases and bioinformatics tools covering the following topics of interest:
1) Different immunophenotypes as biomarkers in the prognosis in tumors.
2) Tumor mutational burden (TMB) and tumor immunotherapy response.
3) Therapeutic targeting of tumor immunophenotypes in the prevention of tumors.
4) Relationship between pathways and immunotherapy.
5) immune checkpoint signaling and tumor immunotherapy.
